October 6, 2020
Fact or Fiction: Experts Share How to Discuss Covid-19 Now and in the Future
Medical analyst Dr. Vin Gupta, a regular on NBC News and MSNBC, included in roster
Darmstadt, Germany, October 6, 2020 OpinePR 🎯 — Every day, we are bombarded by information Covid-19 — how to protect ourselves, which guidelines to follow, new tests and forthcoming vaccines — from so many different sources. How do distinguish fact from fiction?
Leading experts, including Dr. Vin Gupta, will discuss all the facts surrounding the novel coronavirus, and how we should communicate to the public during these challenging times,, during the fifth in a series of live, virtual Pandemic Response Catalyst Conversations.
The six-part Catalyst Conversation series is hosted by the Life Science business of Merck, the Massachusetts Institute of Technology’s (MIT) Center for Collective Intelligence and MIT Media Lab’s Community Biotechnology Initiative.
Media are invited to join the event, which will include a question and answer session. The event will be included in the Global Community Bio Summit’s fourth annual programming, which is expected to draw more than 600 participants from around the world to discuss biotechnology.
· Dr. Vin Gupta, M.P.A., affiliate assistant professor at the Institute for Health Metrics and Evaluation at the University of Washington.
Dr. Gupta is a well-known expert on public health and epidemic preparedness and a practicing critical care physician working with Covid-19 patients since the early days of the outbreak.
· Nick Lindsay, director of journals and open access at MIT Press.
· David Sun Kong, Ph.D., director of MIT Media Lab’s Community Biotechnology Initiative and founder of the Global Community Bio Summit. Dr. Kong will moderate the session.
· Renee Connolly, head of communication and business markets / services at the Life Science business of Merck. Connolly will host the session.
WHEN: Tuesday, October 13, 2020 at 4 p.m. CET.
Interview opportunities available by emailing
WHERE: Tune in at Livestream.com.
WHAT: The Pandemic Response Catalyst Conversation series is part of an initiative developed by the three host organizations to generate open science and data-driven, collaborative solutions.
About the MIT Center for Collective Intelligence
The MIT Center for Collective Intelligence brings together faculty from across MIT to conduct research on how new communications technologies are changing the way people work together. This first-of-its-kind research effort draws on the strengths of many diverse organizations across the Institute including the MIT Media Lab, the Computer Science and Artificial Intelligence Laboratory, the Department of Brain and Cognitive Sciences, and the MIT Sloan School of Management.
For more information, visit https://cci.mit.edu/.
About the MIT Community Biotechnology Initiative The MIT Community Biotechnology Initiative (CBI) of the MIT Media Lab develops tools and technologies to enable the broadest possible participation in biotechnology. Projects include the creation of low-cost enabling hardware, infrastructure for sharing, and new interfaces for artistic expression with biology.
For more information, visit https://www.media.mit.edu/groups/community-bio/overview/.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.
Karen Tiano +49 6151 72 44461